Role of mTOR signaling in tumor cell motility, invasion and metastasis

Current Protein and Peptide Science

Volumn 12, Issue 1, 2011, Pages 30-42

  Zhou, Hongyu ^a   Huang, Shile ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cell motility; Invasion; Metastasis; mTOR; Rapamycin

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 32 DEOXORAPAMYCIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT; EVEROLIMUS; GNE 477; INITIATION FACTOR 4E BINDING PROTEIN 1; KU 0063794; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PP 242; PP 30; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RIDAFOROLIMUS; S6 KINASE; S6 KINASE 1; SAR 943; TEMSIROLIMUS; TORIN 1; TUBERIN; TUBEROUS SCLEROSIS COMPLEX 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; WYE 354; XL 765; ZOTAROLIMUS;

ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; CANCER CELL CULTURE; CARCINOGENESIS; CELL CYCLE; CELL FUNCTION; CELL GROWTH; CELL INVASION; CELL METABOLISM; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); COLON CANCER; COMPLEX FORMATION; DRUG DESIGN; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; FIBROBLAST; HELA CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY ALLOGRAFT REJECTION; KIDNEY CARCINOMA; MAMMAL CELL; METASTASIS; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

EUKARYOTA; MAMMALIA;

EID: 79954516239     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/138920311795659407     Document Type: Review

References (180)

1. Leber, M.F.; Efferth, T. Molecular principles of cancer invasion and metastasis (review). Int. J. Oncol., 2009, 34, 881-895.
2. Woodhouse, E.C.; Chuaqui, R.F.; Liotta, L.A. General mechanisms of metastasis. Cancer, 1997, 80, 1529-1537.
3. Silletti, S.; Paku, S.; Raz, A. Tumor cell motility and metastasis: Autocrine motility factor as an example of ecto/exoenzyme cytokines. Pathol. Oncol. Res., 1997, 3, 230-254.
4. Friedl, P.; Brocker, E.B. The biology of cell locomotion within three-dimensional extracellular matrix. Cell Mol. Life Sci., 2000, 57, 41-64.
5. Liotta, L.A.; Schiffmann, E. Tumour motility factors. Cancer Surv., 1988, 7, 631-652.
6. Friedl, P.; Wolf, K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer, 2003, 3, 362-374.
7. Mitra, S.K.; Hanson, D.A.; Schlaepfer, D.D. Focal adhesion kinase: in command and control of cell motility. Nat. Rev. Mol. Cell Biol., 2005, 6, 56-68.
8. Schmidt, A.; Hall, M.N. Signaling to the actin cytoskeleton. Annu. Rev. Cell Dev. Biol., 1998, 14, 305-338.
9. Lauffenburger, D.A.; Horwitz, A.F. Cell migration: a physically integrated molecular process. Cell, 1996, 84, 359-369.
10. Berven, L.A.; Willard, F.S.; Crouch, M.F. Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration. Exp. Cell Res., 2004, 296, 183-195.
11. Chen, J.S.; Wang, Q.; Fu, X.H.; Huang, X.H.; Chen, X.L.; Cao, L.Q.; Chen, L.Z.; Tan, H.X.; Li, W.; Bi, J.; Zhang, L.J. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol. Res., 2009, 39, 177-186.
12. Liu, L.; Li, F.; Cardelli, J.A.; Martin, K.A.; Blenis, J.; Huang, S. Rapamycin inhibits cell motility by suppression of mTORmediated S6K1 and 4E-BP1 pathways. Oncogene, 2006, 25, 7029-7040.
13. Chiang, G.G.; Abraham, R.T. Targeting the mTOR signaling network in cancer. Trends Mol. Med., 2007, 13, 433-442.
14. Sarbassov, D.D.; Ali, S.M.; Sabatini, D.M. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol., 2005, 17, 596-603.
15. Busch, S.; Renaud, S.J.; Schleussner, E.; Graham, C.H.; Markert, U.R. mTOR mediates human trophoblast invasion through regulation of matrix-remodeling enzymes and is associated with serine phosphorylation of STAT3. Exp. Cell Res., 2009, 315, 1724-1733.
16. Wan, X.; Mendoza, A.; Khanna, C.; Helman, L.J. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res., 2005, 65, 2406-2411.
17. Jung, C.H.; Ro, S.H.; Cao, J.; Otto, N.M.; Kim, D.H. mTOR regulation of autophagy. FEBS Lett., 2010, 584, 1287-1295.
18. Fingar, D.C.; Blenis, J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene, 2004, 23, 3151-3171.
19. Dada, S.; Demartines, N.; Dormond, O. mTORC2 regulates PGE2-mediated endothelial cell survival and migration. Biochem. Biophys. Res. Commun., 2008, 372, 875-879.
20. Sarbassov, D.D.; Ali, S.M.; Kim, D.H.; Guertin, D.A.; Latek, R.R.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol., 2004, 14, 1296-1302.
21. Brown, E.J.; Albers, M.W.; Shin, T.B.; Ichikawa, K.; Keith, C.T.; Lane, W.S.; Schreiber, S.L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature, 1994, 369, 756-758.
22. Chen, Y.; Chen, H.; Rhoad, A.E.; Warner, L.; Caggiano, T.J.; Failli, A.; Zhang, H.; Hsiao, C.L.; Nakanishi, K.; Molnar-Kimber, K.L. A putative sirolimus (rapamycin) effector protein. Biochem. Biophys. Res. Commun., 1994, 203, 1-7.
23. Chiu, M.I.; Katz, H.; Berlin, V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc. Natl. Acad. Sci. USA, 1994, 91, 12574-12578.
24. Sabatini, D.M.; Erdjument-Bromage, H.; Lui, M.; Tempst, P.; Snyder, S.H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell, 1994, 78, 35-43.
25. Abraham, R.T. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr. Opin. Immunol., 1998, 10, 330-336.
26. Keith, C.T.; Schreiber, S.L. PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science, 1995, 270, 50-51.
27. Kunz, J.; Henriquez, R.; Schneider, U.; Deuter-Reinhard, M.; Movva, N.R.; Hall, M.N. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell, 1993, 73, 585-596.
28. Thomas, G.; Hall, M.N. TOR signalling and control of cell growth. Curr. Opin. Cell Biol., 1997, 9, 782-787.
29. Brown, E.J.; Schreiber, S.L. A signaling pathway to translational control. Cell, 1996, 86, 517-520.
30. Canman, C.E.; Lim, D.S.; Cimprich, K.A.; Taya, Y.; Tamai, K.; Sakaguchi, K.; Appella, E.; Kastan, M.B.; Siliciano, J.D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science, 1998, 281, 1677-1679.
31. Yang, Q.; Guan, K.L. Expanding mTOR signaling. Cell Res., 2007, 17, 666-681.
32. Gingras, A.C.; Raught, B.; Sonenberg, N. Regulation of translation initiation by FRAP/mTOR. Genes Dev., 2001, 15, 807-826.
33. Perry, J.; Kleckner, N. The ATRs, ATMs, and TORs are giant HEAT repeat proteins. Cell, 2003, 112, 151-155.
34. Hara, K.; Maruki, Y.; Long, X.; Yoshino, K.; Oshiro, N.; Hidayat, S.; Tokunaga, C.; Avruch, J.; Yonezawa, K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell, 2002, 110, 177-189.
35. Kim, D.H.; Sarbassov, D.D.; Ali, S.M.; Latek, R.R.; Guntur, K.V.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D.M. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell, 2003, 11, 895-904.
36. Sancak, Y.; Thoreen, C.C.; Peterson, T.R.; Lindquist, R.A.; Kang, S.A.; Spooner, E.; Carr, S.A.; Sabatini, D.M. PRAS40 is an insulinregulated inhibitor of the mTORC1 protein kinase. Mol. Cell, 2007, 25, 903-915.
37. Peterson, T.R.; Laplante, M.; Thoreen, C.C.; Sancak, Y.; Kang, S.A.; Kuehl, W.M.; Gray, N.S.; Sabatini, D.M. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell, 2009, 137, 873-886.
38. Wang, L.; Harris, T.E.; Roth, R.A.; Lawrence, J.C., Jr. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J. Biol. Chem., 2007, 282, 20036-20044.
39. Reinhard, C.; Thomas, G.; Kozma, S.C. A single gene encodes two isoforms of the p70 S6 kinase: activation upon mitogenic stimulation. Proc. Natl. Acad. Sci. USA, 1992, 89, 4052-4056.
40. Martin, K.A.; Blenis, J. Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv. Cancer Res., 2002, 86, 1-39.
41. Park, I.H.; Bachmann, R.; Shirazi, H.; Chen, J. Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin. J. Biol. Chem., 2002, 277, 31423-31429.
42. Price, D.J.; Grove, J.R.; Calvo, V.; Avruch, J.; Bierer, B.E. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science, 1992, 257, 973-977.
43. Kozma, S.C.; Thomas, G. Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K. Bioessays, 2002, 24, 65-71.
44. Pearson, R.B.; Dennis, P.B.; Han, J.W.; Williamson, N.A.; Kozma, S.C.; Wettenhall, R.E.; Thomas, G. The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. EMBO J., 1995, 14, 5279-5287.
45. Moser, B.A.; Dennis, P.B.; Pullen, N.; Pearson, R.B.; Williamson, N.A.; Wettenhall, R.E.; Kozma, S.C.; Thomas, G. Dual requirement for a newly identified phosphorylation site in p70s6k. Mol. Cell Biol., 1997, 17, 5648-5655.
46. Saitoh, M.; Pullen, N.; Brennan, P.; Cantrell, D.; Dennis, P.B.; Thomas, G. Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site. J. Biol. Chem., 2002, 277, 20104-20112.
47. Alessi, D.R.; Kozlowski, M.T.; Weng, Q.P.; Morrice, N.; Avruch, J. 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr. Biol., 1998, 8, 69-81.
48. Pullen, N.; Dennis, P.B.; Andjelkovic, M.; Dufner, A.; Kozma, S.C.; Hemmings, B.A.; Thomas, G. Phosphorylation and activation of p70s6k by PDK1. Science, 1998, 279, 707-710.
49. Burnett, P.E.; Barrow, R.K.; Cohen, N.A.; Snyder, S.H.; Sabatini, D.M. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. USA, 1998, 95, 1432-1437.
50. Isotani, S.; Hara, K.; Tokunaga, C.; Inoue, H.; Avruch, J.; Yonezawa, K. Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase alpha in vitro. J. Biol. Chem., 1999, 274, 34493-34498.
51. Montagne, J.; Stewart, M.J.; Stocker, H.; Hafen, E.; Kozma, S.C.; Thomas, G. Drosophila S6 kinase: a regulator of cell size. Science, 1999, 285, 2126-2129.
52. Radimerski, T.; Montagne, J.; Rintelen, F.; Stocker, H.; van der Kaay, J.; Downes, C.P.; Hafen, E.; Thomas, G. dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1. Nat. Cell Biol., 2002, 4, 251-255.
53. Avruch, J.; Belham, C.; Weng, Q.; Hara, K.; Yonezawa, K. The p70 S6 kinase integrates nutrient and growth signals to control translational capacity. Prog. Mol. Subcell. Biol., 2001, 26, 115-154.
54. Jefferies, H.B.; Reinhard, C.; Kozma, S.C.; Thomas, G. Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. Proc. Natl. Acad. Sci. USA, 1994, 91, 4441-4445.
55. Terada, N.; Patel, H.R.; Takase, K.; Kohno, K.; Nairn, A.C.; Gelfand, E.W. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc. Natl. Acad. Sci. USA, 1994, 91, 11477-11481.
56. Stolovich, M.; Tang, H.; Hornstein, E.; Levy, G.; Cohen, R.; Bae, S.S.; Birnbaum, M.J.; Meyuhas, O. Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. Mol. Cell Biol., 2002, 22, 8101-8113.
57. -/-mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogenactivated protein kinase-dependent S6 kinase pathway. Mol. Cell Biol., 2004, 24, 3112-3124.
58. Holz, M.K.; Ballif, B.A.; Gygi, S.P.; Blenis, J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell, 2005, 123, 569-580.
59. Lin, T.A.; Kong, X.; Haystead, T.A.; Pause, A.; Belsham, G.; Sonenberg, N.; Lawrence, J.C., Jr. PHAS-I as a link between mitogen-activated protein kinase and translation initiation. Science, 1994, 266, 653-656.
60. Pause, A.; Belsham, G.J.; Gingras, A.C.; Donze, O.; Lin, T.A.; Lawrence, J.C., Jr.; Sonenberg, N. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature, 1994, 371, 762-767.
61. Poulin, F.; Gingras, A.C.; Olsen, H.; Chevalier, S.; Sonenberg, N. 4E-BP3, a new member of the eukaryotic initiation factor 4Ebinding protein family. J. Biol. Chem., 1998, 273, 14002-14007.
62. Brunn, G.J.; Hudson, C.C.; Sekulic, A.; Williams, J.M.; Hosoi, H.; Houghton, P.J.; Lawrence, J.C., Jr.; Abraham, R.T. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science, 1997, 277, 99-101.
63. Hara, K.; Yonezawa, K.; Kozlowski, M.T.; Sugimoto, T.; Andrabi, K.; Weng, Q.P.; Kasuga, M.; Nishimoto, I.; Avruch, J. Regulation of eIF-4E BP1 phosphorylation by mTOR. J. Biol. Chem., 1997, 272, 26457-26463.
64. Gingras, A.C.; Gygi, S.P.; Raught, B.; Polakiewicz, R.D.; Abraham, R.T.; Hoekstra, M.F.; Aebersold, R.; Sonenberg, N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev., 1999, 13, 1422-1437.
65. Yang, D.Q.; Kastan, M.B. Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat. Cell Biol., 2000, 2, 893-898.
66. Yang, D.; Brunn, G.J.; Lawrence, J.C., Jr. Mutational analysis of sites in the translational regulator, PHAS-I, that are selectively phosphorylated by mTOR. FEBS Lett., 1999, 453, 387-390.
67. Richter, J.D.; Sonenberg, N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature, 2005, 433, 477-480.
68. Shah, O.J.; Anthony, J.C.; Kimball, S.R.; Jefferson, L.S. 4E-BP1 and S6K1: translational integration sites for nutritional and hormonal information in muscle. Am. J. Physiol. Endocrinol. Metab., 2000, 279, E715-729.
69. Jacinto, E.; Loewith, R.; Schmidt, A.; Lin, S.; Ruegg, M.A.; Hall, A.; Hall, M.N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol., 2004, 6, 1122-1128.
70. Frias, M.A.; Thoreen, C.C.; Jaffe, J.D.; Schroder, W.; Sculley, T.; Carr, S.A.; Sabatini, D.M. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr. Biol., 2006, 16, 1865-1870.
71. Pearce, L.R.; Huang, X.; Boudeau, J.; Pawlowski, R.; Wullschleger, S.; Deak, M.; Ibrahim, A.F.; Gourlay, R.; Magnuson, M.A.; Alessi, D.R. Identification of Protor as a novel Rictorbinding component of mTOR complex-2. Biochem. J., 2007, 405, 513-522.
72. Woo, S.Y.; Kim, D.H.; Jun, C.B.; Kim, Y.M.; Haar, E.V.; Lee, S.I.; Hegg, J.W.; Bandhakavi, S.; Griffin, T.J.; Kim, D.H. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. J. Biol. Chem., 2007, 282, 25604-25612.
73. Martin, J.; Masri, J.; Bernath, A.; Nishimura, R.N.; Gera, J. Hsp70 associates with Rictor and is required for mTORC2 formation and activity. Biochem. Biophys. Res. Commun., 2008, 372, 578-583.
74. Thomson, A.W.; Turnquist, H.R.; Raimondi, G. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol., 2009, 9, 324-337.
75. Sarbassov, D.D.; Ali, S.M.; Sengupta, S.; Sheen, J.H.; Hsu, P.P.; Bagley, A.F.; Markhard, A.L.; Sabatini, D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell, 2006, 22, 159-168.
76. Sarbassov, D.D.; Guertin, D.A.; Ali, S.M.; Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 2005, 307, 1098-1101.
77. Lawlor, M.A.; Alessi, D.R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J. Cell Sci., 2001, 114, 2903-2910.
78. Song, G.; Ouyang, G.; Bao, S. The activation of Akt/PKB signaling pathway and cell survival. J. Cell Mol. Med., 2005, 9, 59-71.
79. Garcia-Martinez, J.M.; Alessi, D.R. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum-and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J., 2008, 416, 375-385.
80. Jones, K.T.; Greer, E.R.; Pearce, D.; Ashrafi, K. Rictor/TORC2 regulates Caenorhabditis elegans fat storage, body size, and development through sgk-1. PLoS Biol., 2009, 7, e60.
81. Soukas, A.A.; Kane, E.A.; Carr, C.E.; Melo, J.A.; Ruvkun, G. Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans. Genes Dev., 2009, 23, 496-511.
82. Brunet, A.; Park, J.; Tran, H.; Hu, L.S.; Hemmings, B.A.; Greenberg, M.E. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol. Cell Biol., 2001, 21, 952-965.
83. Amato, R.; D'Antona, L.; Porciatti, G.; Agosti, V.; Menniti, M.; Rinaldo, C.; Costa, N.; Bellacchio, E.; Mattarocci, S.; Fuiano, G.; Soddu, S.; Paggi, M.G.; Lang, F.; Perrotti, N. Sgk1 activates MDM2-dependent p53 degradation and affects cell proliferation, survival, and differentiation. J. Mol. Med., 2009, 87, 1221-1239.
84. Ballou, L.M.; Lin, R.Z. Rapamycin and mTOR kinase inhibitors. J. Chem. Biol., 2008, 1, 27-36.
85. Vezina, C.; Kudelski, A.; Sehgal, S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo), 1975, 28, 721-726.
86. Eng, C.P.; Sehgal, S.N.; Vezina, C. Activity of rapamycin (AY-22,989) against transplanted tumors. J. Antibiot. (Tokyo), 1984, 37, 1231-1237.
87. Douros, J.; Suffness, M. New antitumor substances of natural origin. Cancer Treat. Rev., 1981, 8, 63-87.
88. Linhares, M.M.; Gonzalez, A.M.; Trivino, T.; Melaragno, C.; Moura, R.M.; Garcez, M.H.; Sa, J.R.; Aguiar, W.F.; Succi, T.; Barbosa, C.S.; Pestana, J.O. Simultaneous pancreas-kidney transplantation initial experience. Transplant. Proc., 2003, 35,
89. Sehgal, S.N.; Baker, H.; Vezina, C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. (Tokyo), 1975, 28, 727-732.
90. Huang, S.; Houghton, P.J. Resistance to rapamycin: a novel anticancer drug. Cancer Metastasis Rev., 2001, 20, 69-78.
91. Dilling, M.B.; Dias, P.; Shapiro, D.N.; Germain, G.S.; Johnson, R.K.; Houghton, P.J. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res., 1994, 54, 903-907.
92. Hosoi, H.; Dilling, M.B.; Shikata, T.; Liu, L.N.; Shu, L.; Ashmun, R.A.; Germain, G.S.; Abraham, R.T.; Houghton, P.J. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res., 1999, 59, 886-894.
93. Seufferlein, T.; Rozengurt, E. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res., 1996, 56, 3895-3897.
94. Ogawa, T.; Tokuda, M.; Tomizawa, K.; Matsui, H.; Itano, T.; Konishi, R.; Nagahata, S.; Hatase, O. Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2.8) cells. Biochem. Biophys. Res. Commun., 1998, 249, 226-230.
95. Grewe, M.; Gansauge, F.; Schmid, R.M.; Adler, G.; Seufferlein, T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res., 1999, 59, 3581-3587.
96. Cafferkey, R.; Young, P.R.; McLaughlin, M.M.; Bergsma, D.J.; Koltin, Y.; Sathe, G.M.; Faucette, L.; Eng, W.K.; Johnson, R.K.; Livi, G.P. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol. Cell Biol., 1993, 13, 6012-6023.
97. Heitman, J.; Movva, N.R.; Hall, M.N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science, 1991, 253, 905-909.
98. Chen, J.; Zheng, X.F.; Brown, E.J.; Schreiber, S.L. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc. Natl. Acad. Sci. USA, 1995, 92, 4947-4951.
99. Choi, J.; Chen, J.; Schreiber, S.L.; Clardy, J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science, 1996, 273, 239-242.
100. Sabers, C.J.; Martin, M.M.; Brunn, G.J.; Williams, J.M.; Dumont, F.J.; Wiederrecht, G.; Abraham, R.T. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem., 1995, 270, 815-822.
101. Yu, K.; Toral-Barza, L.; Discafani, C.; Zhang, W.G.; Skotnicki, J.; Frost, P.; Gibbons, J.J. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer, 2001, 8, 249-258.
102. Boulay, A.; Zumstein-Mecker, S.; Stephan, C.; Beuvink, I.; Zilbermann, F.; Haller, R.; Tobler, S.; Heusser, C.; O'Reilly, T.; Stolz, B.; Marti, A.; Thomas, G.; Lane, H.A. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res., 2004, 64, 252-261.
103. Mahalingam, D.; Sankhala, K.; Mita, A.; Giles, F.J.; Mita, M.M. Targeting the mTOR pathway using deforolimus in cancer therapy. Future Oncol., 2009, 5, 291-303.
104. Rizzieri, D.A.; Feldman, E.; Dipersio, J.F.; Gabrail, N.; Stock, W.; Strair, R.; Rivera, V.M.; Albitar, M.; Bedrosian, C.L.; Giles, F.J. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res., 2008, 14, 2756-2762.
105. Rini, B.I. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin. Cancer Res., 2008, 14, 1286-1290.
106. Wolpin, B.M.; Hezel, A.F.; Abrams, T.; Blaszkowsky, L.S.; Meyerhardt, J.A.; Chan, J.A.; Enzinger, P.C.; Allen, B.; Clark, J.W.; Ryan, D.P.; Fuchs, C.S. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J. Clin. Oncol., 2009, 27, 193-198.
107. Heffron, T.P.; Berry, M.; Castanedo, G.; Chang, C.; Chuckowree, I.; Dotson, J.; Folkes, A.; Gunzner, J.; Lesnick, J.D.; Lewis, C.; Mathieu, S.; Nonomiya, J.; Olivero, A.; Pang, J.; Peterson, D.; Salphati, L.; Sampath, D.; Sideris, S.; Sutherlin, D.P.; Tsui, V.; Wan, N.C.; Wang, S.; Wong, S.; Zhu, B.Y. Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor. Bioorg. Med. Chem. Lett., 20, 2408-2411.
108. Maira, S.M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia-Echeverria, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther., 2008, 7, 1851-1863.
109. Zou, Z.Q.; Zhang, X.H.; Wang, F.; Shen, Q.J.; Xu, J.; Zhang, L.N.; Xing, W.H.; Zhuo, R.J.; Li, D. A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells. Int. J. Mol. Med., 2009, 24, 97-101.
110. Molckovsky, A.; Siu, L.L. First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting. J. Hematol. Oncol., 2008, 1, 20.
111. O'Reilly, K.E.; Rojo, F.; She, Q.B.; Solit, D.; Mills, G.B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D.J.; Ludwig, D.L.; Baselga, J.; Rosen, N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res., 2006, 66, 1500-1508.
112. Thoreen, C.C.; Kang, S.A.; Chang, J.W.; Liu, Q.; Zhang, J.; Gao, Y.; Reichling, L.J.; Sim, T.; Sabatini, D.M.; Gray, N.S. An ATPcompetitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem., 2009, 284, 8023-8032.
113. Feldman, M.E.; Apsel, B.; Uotila, A.; Loewith, R.; Knight, Z.A.; Ruggero, D.; Shokat, K.M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol., 2009, 7, e38.
114. Garcia-Martinez, J.M.; Moran, J.; Clarke, R.G.; Gray, A.; Cosulich, S.C.; Chresta, C.M.; Alessi, D.R. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J., 2009.
115. Yu, K.; Toral-Barza, L.; Shi, C.; Zhang, W.G.; Lucas, J.; Shor, B.; Kim, J.; Verheijen, J.; Curran, K.; Malwitz, D.J.; Cole, D.C.; Ellingboe, J.; Ayral-Kaloustian, S.; Mansour, T.S.; Gibbons, J.J.; Abraham, R.T.; Nowak, P.; Zask, A. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res., 2009, 69, 6232-6240.
116. Beevers, C.S.; Chen, L.; Liu, L.; Luo, Y.; Webster, N.J.; Huang, S. Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Cancer Res., 2009, 69, 1000-1008.
117. Jiang, H.; Shang, X.; Wu, H.; Gautam, S.C.; Al-Holou, S.; Li, C.; Kuo, J.; Zhang, L.; Chopp, M. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J. Exp. Ther. Oncol., 2009, 8, 25-33.
118. Brito, P.M.; Devillard, R.; Negre-Salvayre, A.; Almeida, L.M.; Dinis, T.C.; Salvayre, R.; Auge, N. Resveratrol inhibits the mTOR mitogenic signaling evoked by oxidized LDL in smooth muscle cells. Atherosclerosis, 2009, 205, 126-134.
119. Zhang, Q.; Kelly, A.P.; Wang, L.; French, S.W.; Tang, X.; Duong, H.S.; Messadi, D.V.; Le, A.D. Green tea extract and (-)-epigallocatechin-3-gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3K/AkT signaling pathways. J. Invest. Dermatol., 2006, 126, 2607-2613.
120. Anastasius, N.; Boston, S.; Lacey, M.; Storing, N.; Whitehead, S.A. Evidence that low-dose, long-term genistein treatment inhibits oestradiol-stimulated growth in MCF-7 cells by down-regulation of the PI3-kinase/Akt signalling pathway. J. Steroid Biochem. Mol. Biol., 2009, 116, 50-55.
121. Nakamura, Y.; Yogosawa, S.; Izutani, Y.; Watanabe, H.; Otsuji, E.; Sakai, T. A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. Mol. Cancer, 2009, 8, 100.
122. Kong, D.; Banerjee, S.; Huang, W.; Li, Y.; Wang, Z.; Kim, H.R.; Sarkar, F.H. Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in plateletderived growth factor-D-overexpressing PC3 cells. Cancer Res., 2008, 68, 1927-1934.
123. Chan, M.M.; Huang, H.I.; Fenton, M.R.; Fong, D. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem. Pharmacol., 1998, 55, 1955-1962.
124. Beevers, C.S.; Li, F.; Liu, L.; Huang, S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int. J. Cancer, 2006, 119, 757-764.
125. Johnson, S.M.; Gulhati, P.; Arrieta, I.; Wang, X.; Uchida, T.; Gao, T.; Evers, B.M. Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Anticancer Res., 2009, 29, 3185-3190.
126. Hardwick, J.S.; Kuruvilla, F.G.; Tong, J.K.; Shamji, A.F.; Schreiber, S.L. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. Proc. Natl. Acad. Sci. USA, 1999, 96, 14866-14870.
127. Cardenas, M.E.; Cutler, N.S.; Lorenz, M.C.; Di Como, C.J.; Heitman, J. The TOR signaling cascade regulates gene expression in response to nutrients. Genes Dev., 1999, 13, 3271-3279.
128. Beck, T.; Hall, M.N. The TOR signalling pathway controls nuclear localization of nutrient-regulated transcription factors. Nature, 1999, 402, 689-692.
129. Jacinto, E.; Hall, M.N. Tor signalling in bugs, brain and brawn. Nat. Rev. Mol. Cell Biol., 2003, 4, 117-126.
130. Schmidt, A.; Kunz, J.; Hall, M.N. TOR2 is required for organization of the actin cytoskeleton in yeast. Proc. Natl. Acad. Sci. USA, 1996, 93, 13780-13785.
131. Masri, J.; Bernath, A.; Martin, J.; Jo, O.D.; Vartanian, R.; Funk, A.; Gera, J. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res., 2007, 67, 11712-11720.
132. Liu, L.; Chen, L.; Chung, J.; Huang, S. Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene, 2008, 27, 4998-5010.
133. Sakakibara, K.; Liu, B.; Hollenbeck, S.; Kent, K.C. Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin. Am. J. Physiol. Heart Circ. Physiol., 2005, 288, H2861-2868.
134. Lamouille, S.; Derynck, R. Cell size and invasion in TGF-betainduced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J. Cell Biol., 2007, 178, 437-451.
135. Sun, J.; Marx, S.O.; Chen, H.J.; Poon, M.; Marks, A.R.; Rabbani, L.E. Role for p27(Kip1) in vascular smooth muscle cell migration. Circulation, 2001, 103, 2967-2972.
136. Poon, M.; Marx, S.O.; Gallo, R.; Badimon, J.J.; Taubman, M.B.; Marks, A.R. Rapamycin inhibits vascular smooth muscle cell migration. J. Clin. Invest., 1996, 98, 2277-2283.
137. Attoub, S.; Noe, V.; Pirola, L.; Bruyneel, E.; Chastre, E.; Mareel, M.; Wymann, M.P.; Gespach, C. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. FASEB J., 2000, 14, 2329-2338.
138. Gomez-Cambronero, J. Rapamycin inhibits GM-CSF-induced neutrophil migration. FEBS Lett., 2003, 550, 94-100.
139. Wong, A.S.; Roskelley, C.D.; Pelech, S.; Miller, D.; Leung, P.C.; Auersperg, N. Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation. Exp. Cell Res., 2004, 299, 248-256.
140. Kwon, Y.S.; Hong, H.S.; Kim, J.C.; Shin, J.S.; Son, Y. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest. Ophthalmol. Vis. Sci., 2005, 46, 454-460.
141. Crouch, M.F. Regulation of thrombin-induced stress fibre formation in Swiss 3T3 cells by the 70-kDa S6 kinase. Biochem. Biophys. Res. Commun., 1997, 233, 193-199.
142. Zhou, H.Y.; Wong, A.S. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology, 2006, 147, 2557-2566.
143. Lin, M.; van Golen, K.L. Rho-regulatory proteins in breast cancer cell motility and invasion. Breast Cancer Res. Treat., 2004, 84, 49-60.
144. Reddy, K.B.; Nabha, S.M.; Atanaskova, N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev., 2003, 22, 395-403.
145. O'Connor, R. Regulation of IGF-I receptor signaling in tumor cells. Horm. Metab. Res., 2003, 35, 771-777.
146. Benefield, J.; Meisinger, J.; Petruzzelli, G.J.; Young, M.R. Endothelial cell response to human head and neck squamous cell carcinomas involves downregulation of protein phosphatases-1/2A, cytoskeletal depolymerization and increased motility. Invasion Metastasis, 1997, 17, 210-220.
147. Jackson, J.L.; Young, M.R. Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants. Clin. Exp. Metastasis, 2003, 20, 357-364.
148. Jung, I.D.; Lee, J.; Yun, S.Y.; Park, C.G.; Choi, W.S.; Lee, H.W.; Choi, O.H.; Han, J.W.; Lee, H.Y. Cdc42 and Rac1 are necessary for autotaxin-induced tumor cell motility in A2058 melanoma cells. FEBS Lett., 2002, 532, 351-356.
149. Chen, J.Y.; Hung, C.C.; Huang, K.L.; Chen, Y.T.; Liu, S.Y.; Chiang, W.F.; Chen, H.R.; Yen, C.Y.; Wu, Y.J.; Ko, J.Y.; Jou, Y.S. Src family kinases mediate betel quid-induced oral cancer cell motility and could be a biomarker for early invasion in oral squamous cell carcinoma. Neoplasia, 2008, 10, 1393-1401.
150. Harwood, F.C.; Shu, L.; Houghton, P.J. mTORC1 signaling can regulate growth factor activation of p44/42 mitogen-activated protein kinases through protein phosphatase 2A. J. Biol. Chem., 2008, 283, 2575-2585.
151. Liu, L.; Chen, L.; Luo, Y.; Chen, W.; Zhou, H.; Xu, B.; Han, X.; Shen, T.; Huang, S. Rapamycin inhibits IGF-1 stimulated cell motility through PP2A pathway. PLoS One, 2010, 5, e10578.
152. Wullschleger, S.; Loewith, R.; Hall, M.N. TOR signaling in growth and metabolism. Cell, 2006, 124, 471-484.
153. Schmidt, A.; Bickle, M.; Beck, T.; Hall, M.N. The yeast phosphatidylinositol kinase homolog TOR2 activates RHO1 and RHO2 via the exchange factor ROM2. Cell, 1997, 88, 531-542.
154. Audhya, A.; Loewith, R.; Parsons, A.B.; Gao, L.; Tabuchi, M.; Zhou, H.; Boone, C.; Hall, M.N.; Emr, S.D. Genome-wide lethality screen identifies new PI4,5P2 effectors that regulate the actin cytoskeleton. EMBO J., 2004, 23, 3747-3757.
155. Fadri, M.; Daquinag, A.; Wang, S.; Xue, T.; Kunz, J. The pleckstrin homology domain proteins Slm1 and Slm2 are required for actin cytoskeleton organization in yeast and bind phosphatidylinositol-4,5-bisphosphate and TORC2. Mol. Biol. Cell, 2005, 16, 1883-1900.
156. Kamada, Y.; Fujioka, Y.; Suzuki, N.N.; Inagaki, F.; Wullschleger, S.; Loewith, R.; Hall, M.N.; Ohsumi, Y. Tor2 directly phosphorylates the AGC kinase Ypk2 to regulate actin polarization. Mol. Cell Biol., 2005, 25, 7239-7248.
157. Clark, E.A.; Golub, T.R.; Lander, E.S.; Hynes, R.O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature, 2000, 406, 532-535.
158. Keely, P.; Parise, L.; Juliano, R. Integrins and GTPases in tumour cell growth, motility and invasion. Trends Cell Biol., 1998, 8, 101-106.
159. del Peso, L.; Hernandez-Alcoceba, R.; Embade, N.; Carnero, A.; Esteve, P.; Paje, C.; Lacal, J.C. Rho proteins induce metastatic properties in vivo. Oncogene, 1997, 15, 3047-3057.
160. Hernandez-Negrete, I.; Carretero-Ortega, J.; Rosenfeldt, H.; Hernandez-Garcia, R.; Calderon-Salinas, J.V.; Reyes-Cruz, G.; Gutkind, J.S.; Vazquez-Prado, J. P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration. J. Biol. Chem., 2007, 282, 23708-23715.
161. Yoeli-Lerner, M.; Yiu, G.K.; Rabinovitz, I.; Erhardt, P.; Jauliac, S.; Toker, A. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol. Cell, 2005, 20, 539-550.
162. Irie, H.Y.; Pearline, R.V.; Grueneberg, D.; Hsia, M.; Ravichandran, P.; Kothari, N.; Natesan, S.; Brugge, J.S. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J. Cell Biol., 2005, 171, 1023-1034.
163. Arboleda, M.J.; Lyons, J.F.; Kabbinavar, F.F.; Bray, M.R.; Snow, B.E.; Ayala, R.; Danino, M.; Karlan, B.Y.; Slamon, D.J. Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res., 2003, 63, 196-206.
164. Schaller, M.D. Paxillin: a focal adhesion-associated adaptor protein. Oncogene, 2001, 20, 6459-6472.
165. Guba, M.; von Breitenbuch, P.; Steinbauer, M.; Koehl, G.; Flegel, S.; Hornung, M.; Bruns, C.J.; Zuelke, C.; Farkas, S.; Anthuber, M.; Jauch, K.W.; Geissler, E.K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med., 2002, 8, 128-135.
166. Luan, F.L.; Hojo, M.; Maluccio, M.; Yamaji, K.; Suthanthiran, M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation, 2002, 73, 1565-1572.
167. Luan, F.L.; Ding, R.; Sharma, V.K.; Chon, W.J.; Lagman, M.; Suthanthiran, M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int., 2003, 63, 917-926.
168. Boffa, D.J.; Luan, F.; Thomas, D.; Yang, H.; Sharma, V.K.; Lagman, M.; Suthanthiran, M. Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin. Cancer Res., 2004, 10, 293-300.
169. Gould, K.L.; Bretscher, A.; Esch, F.S.; Hunter, T. cDNA cloning and sequencing of the protein-tyrosine kinase substrate, ezrin, reveals homology to band 4.1. EMBO J., 1989, 8, 4133-4142.
170. Fazioli, F.; Wong, W.T.; Ullrich, S.J.; Sakaguchi, K.; Appella, E.; Di Fiore, P.P. The ezrin-like family of tyrosine kinase substrates: receptor-specific pattern of tyrosine phosphorylation and relationship to malignant transformation. Oncogene, 1993, 8, 1335-1345.
171. Tsukita, S.; Oishi, K.; Sato, N.; Sagara, J.; Kawai, A.; Tsukita, S. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J. Cell Biol., 1994, 126, 391-401.
172. Huber, S.; Bruns, C.J.; Schmid, G.; Hermann, P.C.; Conrad, C.; Niess, H.; Huss, R.; Graeb, C.; Jauch, K.W.; Heeschen, C.; Guba, M. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int., 2007, 71, 771-777.
173. Kobayashi, S.; Kishimoto, T.; Kamata, S.; Otsuka, M.; Miyazaki, M.; Ishikura, H. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci., 2007, 98, 726-733.
174. Lin, J.; Lalani, A.S.; Harding, T.C.; Gonzalez, M.; Wu, W.W.; Luan, B.; Tu, G.H.; Koprivnikar, K.; VanRoey, M.J.; He, Y.; Alitalo, K.; Jooss, K. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res., 2005, 65, 6901-6909.
175. Roberts, N.; Kloos, B.; Cassella, M.; Podgrabinska, S.; Persaud, K.; Wu, Y.; Pytowski, B.; Skobe, M. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res., 2006, 66, 2650-2657.
176. Takizawa, H.; Kondo, K.; Fujino, H.; Kenzaki, K.; Miyoshi, T.; Sakiyama, S.; Tangoku, A. The balance of VEGF-C and VEGFR-3 mRNA is a predictor of lymph node metastasis in non-small cell lung cancer. Br. J. Cancer, 2006, 95, 75-79.
177. Matsuo, M.; Yamada, S.; Koizumi, K.; Sakurai, H.; Saiki, I. Tumour-derived fibroblast growth factor-2 exerts lymphangiogenic effects through Akt/mTOR/p70S6kinase pathway in rat lymphatic endothelial cells. Eur. J. Cancer, 2007, 43, 1748-1754.
178. Hammer, T.; Tritsaris, K.; Hubschmann, M.V.; Gibson, J.; Nisato, R.E.; Pepper, M.S.; Dissing, S. IL-20 activates human lymphatic endothelial cells causing cell signalling and tube formation. Microvasc. Res., 2009, 78, 25-32.
179. Hammer, T.; Tritsaris, K.; Hubschmann, M.V.; Gibson, J.; Nisato, R.E.; Pepper, M.S.; Dissing, S. IL-20 activates human lymphatic endothelial cells causing cell signalling and tube formation. Microvasc. Res., 2009, 78 (1), 25-32.
180. Yang, Z.; Lei, Z.; Li, B.; Zhou, Y.; Zhang, G.M.; Feng, Z.H.; Zhang, B.; Shen, G.X.; Huang, B. Rapamycin inhibits lung metastasis of B16 melanoma cells through down-regulating alphav integrin expression and up-regulating apoptosis signaling. Cancer Sci., 2010, 101, 494-500.